Investors

AIM Rule 26 Information

This area of the web site contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules.

Shareholder Information

Other Exchanges and Trading Platforms
Shares in Issue
Significant Shareholdings
Director Shareholdings
Shares Not in Public Hands
Restrictions in Transfer of AIM Securities
UK City Code on Takeovers and Mergers

see Shareholder Information

Advisors

see Advisors

Announcements and Notifications

see News

Q&A with LungLife AI's CEO, Paul Pagano

Half-year Report For The Six Months Ended 30 June 2023

Featured News

September 28, 2023

Clinical validation study update

LungLife AI, Inc.(the “Company” or “LungLife”) LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, provides an update on the Company’s clinical validation study for its LungLB® test. As stated in the Company’s half-year report on 8 August 2023, LungLife is currently focussed on preparing data from […]

• Read More

August 14, 2023

Director share purchases

LungLife AI, Inc. (the “Company” or “LungLife”) Director share purchases LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces that it has received notification of the following transactions in the Company’s common shares of US $0.0001 each (“Common Shares”) undertaken by directors. On 14 August 2023, […]

• Read More

1 2 3 … 24 Next »

More News